The September 9, 2025 warning-letter wave
This is one entry from the TitrateLab Vendor Graveyard, a dated, primary-source archive of peptide-market shutdowns, exit scams, and enforcement actions. Documented as September 9, 2025. Sources for this entry are named inline below and numbered in full on the parent archive page.
Order-of-magnitude jump from the four December 2024 letters. Targeted GLP-1 compounders and manufacturers. 15-day response window. Example: GLP-1 Solution 715883.
The FDA issued the letters to US and international companies compounding or manufacturing semaglutide and tirzepatide. The letters primarily targeted false or misleading marketing claims: statements that compounded products were “generic versions” of FDA-approved GLP-1s, or that they contained the “same active ingredient” as brand-name drugs. The FDA gave recipients 15 working days to respond with a corrective action plan.
Why it still matters: most operators we talked to point to the September 9 wave as the trigger for Peptide Sciences’ voluntary shutdown five months later. The math shifted: continuing to operate at Peptide Sciences’ scale would have meant becoming the next headline FDA action, and the cost of that outcome exceeded the remaining profitable years of grey-market operation. Specific named recipients that appeared on the FDA’s warning-letter index included GLP-1 Solution and roughly 49 others; the full list is maintained in the FDA’s public warning letter database.